Case Control Study
Copyright ©The Author(s) 2020.
World J Clin Cases. Jun 26, 2020; 8(12): 2473-2483
Published online Jun 26, 2020. doi: 10.12998/wjcc.v8.i12.2473
Table 1 Clinical characteristics of multiple system atrophy patients, Parkinson disease patients and controls
MSAPDControlP value
All
Subjects, n495050-
Age, yr61.7 ± 7.761.4 ± 7.558.5 ± 7.50.077
Female/male, n26/2326/2430/200.683
Age of onset, yr58.7 ± 7.456.6 ± 7.1-
MSA-P/MSA-C, n30/20---
Probable/Possible, n31/18---
Clinical rate scales (UMSARSII/UPDRSIII)19.5 ± 6.4 (UMSARSII)26.1 ± 13.2 (UPDRSIII)- --
GDF15, pg/mL1105.69 (984.24)506.70 (346.80)313.85 (247.76)0.000
Table 2 Serum levels of growth differentiation factor 15 in different subgroups of multiple system atrophy
SubgroupsGDF15, pg/mLP value
Age of onset
> 50 yr1156.99 (1028.41)0.185
≤ 50 yr795.32 (605.42)
Gender
Female795.31 (698.54)0.043
Male1311.84 (1214.16)
Clinical subtype
MSA-P1121.82 (897.09)0.622
MSA-C916.14 (1009.59)
Diagnosis criteria
Probable887.55 (1004.50)0.561
Possible1182.16 (753.32)
Duration
> 3 yr1393.79 (1021.36)0.000
≤ 3 yr612.31 (527.96)
Table 3 Receiver-operating characteristic curve analysis of serum growth differentiation factor 15 levels as a potential multiple system atrophy diagnostic biomarker
GroupSubtypeAUCSE95%CIP valueCutoff, pg/mLSensitivity, %Specificity, %
MSA vs ControlOverall0.9290.0270.876-0.9810.000470.4285.788.0
Male0.9540.0300.896-1.0000.000552.1082.6100.0
Female0.9050.0440.820-0.9900.000470.4280.890.0
MSA vs PDOverall0.7650.0480.671-0.8590.0001075.9151.096.0
Male0.7720.0720.630-0.9140.0011075.9165.295.8
Female0.7830.0660.654-0.9110.000616.3965.488.5